Search results for "Transforming growth factor"

showing 10 items of 294 documents

Urinary- and Plasma-Derived Exosomes Reveal a Distinct MicroRNA Signature Associated With Albuminuria in Hypertension.

2021

Urinary albumin excretion (UAE) is a marker of cardiovascular risk and renal damage in hypertension. MicroRNAs (miRNAs) packaged into exosomes function as paracrine effectors in cell communication and the kidney is not exempt. This study aimed to state an exosomal miRNA profile/signature associated to hypertension with increased UAE and the impact of profibrotic TGF-β1 (transforming growth factor β1) on exosomes miRNA release. Therefore, exosomes samples from patients with hypertension with/without UAE were isolated and characterized. Three individual and unique small RNA libraries from each subject were prepared (total plasma, urinary, and plasma-derived exosomes) for next-generation sequ…

0301 basic medicineMaleDown-Regulation030204 cardiovascular system & hematologyExosomesTransforming Growth Factor beta103 medical and health sciencesParacrine signalling0302 clinical medicinemicroRNAInternal MedicinemedicineAlbuminuriaHumansGene Regulatory NetworksKEGGCells CulturedAgedKidneybusiness.industryPodocytesReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingMiddle AgedMicrovesiclesMicroRNAs030104 developmental biologyReal-time polymerase chain reactionmedicine.anatomical_structureHypertensionAlbuminuriaCancer researchFemalemedicine.symptombusinessTransforming growth factorHypertension (Dallas, Tex. : 1979)
researchProduct

Fasciola hepatica reinfection potentiates a mixed Th1/Th2/Th17/Treg response and correlates with the clinical phenotypes of anemia.

2016

Background: Fascioliasis is a severe zoonotic disease of worldwide extension caused by liver flukes. In human fascioliasis hyperendemic areas, reinfection and chronicity are the norm and anemia is the main sign. Herein, the profile of the Th1/Th2/Th17/Treg expression levels is analyzed after reinfection, correlating them with their corresponding hematological biomarkers of morbidity. Methodology/Principal findings: The experimental design reproduces the usual reinfection/chronicity conditions in human fascioliasis endemic areas and included Fasciola hepatica primo-infected Wistar rats (PI) and rats reinfected at 8 weeks (R8), and at 12 weeks (R12), and negative control rats. In a cross-sect…

0301 basic medicineMalePhysiologymedicine.medical_treatmentSnailslcsh:MedicineGene ExpressionImmune PhysiologyGene expressionMedicine and Health Scienceslcsh:ScienceImmune ResponseInnate Immune SystemMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionFOXP3hemic and immune systemsImmunosuppressionEBI3AnemiaForkhead Transcription FactorsHematologyThymusInterleukin-10Interleukin 10medicine.anatomical_structureHelminth InfectionsCytokinesResearch ArticleNeglected Tropical DiseasesFascioliasisImmunologychemical and pharmacologic phenomenaSpleenBiologyTransforming Growth Factor beta103 medical and health sciencesImmune systemTh2 CellsGeneticsParasitic DiseasesmedicineFasciola hepaticaAnimalsRats WistarCell ProliferationInterleukinslcsh:RBiology and Life SciencesMolecular DevelopmentFasciola hepaticaTh1 CellsTropical Diseasesbiology.organism_classificationRats030104 developmental biologyCross-Sectional StudiesImmune SystemImmunologyTh17 Cellslcsh:QSpleenDevelopmental Biology
researchProduct

Mutations in SKI in Shprintzen-Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization.

2020

ABSTRACTShprintzen-Goldberg syndrome (SGS) is a multisystemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys-Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-β signaling. In SGS patients, heterozygous point mutations have been mapped to the transcriptional corepressor SKI, which is a negative regulator of TGF-β signaling that is rapidly degraded upon ligand stimulation. The molecular consequences of these mutations, however, are not understood. Here we use a combination of structural biology, genome editing and biochemistry to show that SGS mutations in SKI abolish its binding to phosphorylated SMAD2 and SMAD3. This resul…

0301 basic medicineMaleSMADmedicine.disease_causeMarfan SyndromeActivin0302 clinical medicineGenome editingTransforming Growth Factor betaGene expressionBiology (General)MutationShprintzen-Goldberg syndromeGeneral NeuroscienceQRShprintzen–Goldberg syndromeGeneral MedicineLigand (biochemistry)Chromosomes and Gene ExpressionCell biologyDNA-Binding ProteinsMedicinePhosphorylationFemaleSignal TransductionResearch ArticleHumanTGF-βQH301-705.5ScienceBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesCraniosynostosesstomatognathic systemBiochemistry and Chemical BiologyProto-Oncogene ProteinsmedicineHumansGeneral Immunology and MicrobiologyPoint mutationmedicine.diseaseSKIArachnodactyly030104 developmental biologyStructural biologyMutation030217 neurology & neurosurgerySMADTransforming growth factoreLife
researchProduct

Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibrobla…

2018

Abstract Background Fibrosis may be considered the hallmark of systemic sclerosis (SSc), the end stage triggered by different pathological events. Transforming growth factor-β (TGF-β) and platelet-derived growth factor BB (PDGF-BB) are profibrotic molecules modulating myofibroblast differentiation and proliferation, respectively. There is evidence linking CD248 with these two molecules, both highly expressed in patients with SSc, and suggesting that CD248 may be a therapeutic target for several diseases. The aim of this work was to evaluate the expression of CD248 in SSc skin and its ability to modulate SSc fibrotic process. Methods After ethical approval was obtained, skin biopsies were co…

0301 basic medicineMalelcsh:Diseases of the musculoskeletal systemProton Pump InhibitorFibrosiCellular differentiationmedicine.medical_treatmentSystemic sclerosiFibrosisImmunology and AllergyMedicineMyofibroblastsskin and connective tissue diseasesCells CulturedSkinintegumentary systemCell DifferentiationMiddle AgedMesenchymal Stem CellBenzamidesSystemic sclerosisFemaleMyofibroblastResearch ArticleHumanAdultStromal cellImmunology03 medical and health sciencesYoung AdultRheumatologyBenzamideAntigens CDAntigens NeoplasmHumansGene silencingCell ProliferationMyofibroblastScleroderma Systemicbusiness.industryGrowth factorMesenchymal stem cellStromal CellMesenchymal Stem CellsProton Pump Inhibitorsmedicine.diseaseFibrosisCD248Settore MED/16 - Reumatologia030104 developmental biologyCancer researchStromal Cellslcsh:RC925-935CD248; Fibrosis; Systemic sclerosis; Rheumatology; Immunology and Allergy; ImmunologybusinessTransforming growth factor
researchProduct

Stem Cell-Derived, microRNA-Carrying Extracellular Vesicles: A Novel Approach to Interfering with Mesangial Cell Collagen Production in a Hyperglycae…

2016

Extracellular vesicles (EVs) that are derived from stem cells are proving to be promising therapeutic options. We herein investigate the therapeutic potential of EVs that have been derived from different stem cell sources, bone-marrow (MSC) and human liver (HLSC), on mesangial cells (MCs) exposed to hyperglycaemia. By expressing a dominant negative STAT5 construct (ΔNSTAT5) in HG-cultured MCs, we have demonstrated that miR-21 expression is under the control of STAT5, which translates into Transforming Growth Factor beta (TGFβ) expression and collagen production. A number of approaches have been used to show that both MSC- and HLSC-derived EVs protect MCs from HG-induced damage via the trans…

0301 basic medicineMolecular biologyCellGene Expressionlcsh:MedicineBiochemistry0302 clinical medicineAnimal CellsChronic Kidney DiseaseMedicine and Health SciencesSTAT5 Transcription FactorRNA Processing Post-Transcriptionallcsh:ScienceSTAT5Energy-Producing OrganellesCells CulturedMultidisciplinarybiologyMesangial cellStem CellsVector ConstructionCell biologyMitochondriaEnzymesmedicine.anatomical_structureBiochemistryNephrology030220 oncology & carcinogenesisMesangial CellsCollagenStem cellCellular TypesCellular Structures and OrganellesOxidoreductasesLuciferaseResearch ArticleCollagen Type IVBioenergeticsDNA constructionModels Biological03 medical and health sciencesExtracellular VesiclesmicroRNAmedicineGene Expression and Vector TechniquesGeneticsHumansVesiclesCell ProliferationMolecular Biology Assays and Analysis TechniquesCell growthMesenchymal stem celllcsh:RBiology and Life SciencesProteinsMesenchymal Stem CellsTransforming growth factor betaCell BiologyResearch and analysis methodsMicroRNAs030104 developmental biologyMolecular biology techniquesGlucoseHyperglycemiabiology.proteinEnzymologylcsh:QCollagensPLoS ONE
researchProduct

Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma

2017

Hepatocellular carcinoma (HCC) is one of the most common cancers in the world, and represents the second most frequently cancer and third most common cause of death from cancer worldwide. At advanced stage, HCC is a highly aggressive tumor with a poor prognosis and with very limited response to common therapies. Therefore, there is still the need for new effective and well-tolerated therapeutic strategies. Molecular-targeted therapies hold promise for HCC treatment. One promising molecular target is the multifunctional serine/threonine kinase glycogen synthase kinase 3 (GSK-3). The roles of GSK-3β in HCC remain controversial, several studies suggested a possible role of GSK-3β as a tumor …

0301 basic medicinePathologymedicine.medical_specialtyCancer ResearchCarcinoma HepatocellularEpithelial-Mesenchymal TransitionTumor suppressor geneAntineoplastic Agentsmacromolecular substancesBiologyMetastasisGlycogen Synthase Kinase 303 medical and health sciencesWnt0302 clinical medicineGeneticTransforming Growth Factor betaGSK-3GeneticsmedicineHumansHedgehog ProteinsMolecular Targeted TherapyInsulin-Like Growth Factor IHCCIGFβ-cateninGlycogen synthaseHedgehogMolecular Biologybeta CateninGSK-3Glycogen Synthase Kinase 3 betaReceptors NotchLiver NeoplasmsWnt signaling pathwayCancermedicine.diseaseSurvival Analysisdigestive system diseasesGene Expression Regulation Neoplastic030104 developmental biology030220 oncology & carcinogenesisHepatocellular carcinomabiology.proteinCancer researchMolecular MedicineHedgehogSignal Transduction
researchProduct

TGF-β Serum Levels in Diabetic Retinopathy Patients and the Role of Anti-VEGF Therapy.

2020

Transforming growth factor &beta

0301 basic medicinePlacental growth factorMaleVascular Endothelial Growth Factor Aserum biomarkersGastroenterologylcsh:ChemistryPathogenesischemistry.chemical_compound0302 clinical medicineTransforming Growth Factor betaMedicineMolecular Targeted Therapylcsh:QH301-705.5SpectroscopyAfliberceptAged 80 and overGeneral MedicineDiabetic retinopathyTGFComputer Science ApplicationsVascular endothelial growth factor ABiomarker (medicine)Intercellular Signaling Peptides and ProteinsFemaleTomography Optical Coherencemedicine.drugmedicine.medical_specialtyanti-VEGFAAnti-VEGFA; Diabetic retinopathy; Serum biomarkers; TGFCatalysisArticleProinflammatory cytokineInorganic Chemistry03 medical and health sciencesTGFβInternal medicineHumansPhysical and Theoretical ChemistryMolecular BiologyAgedDiabetic Retinopathybusiness.industryOrganic Chemistrymedicine.diseaseeye diseases030104 developmental biologylcsh:Biology (General)lcsh:QD1-999chemistryDiabetes Mellitus Type 2ROC Curve030221 ophthalmology & optometryGlycated hemoglobinbusinessBiomarkersInternational journal of molecular sciences
researchProduct

Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors

2017

Abstract Rhomboids are intramembrane serine proteases with diverse physiological functions in organisms ranging from archaea to humans. Crystal structure analysis has provided a detailed understanding of the catalytic mechanism, and rhomboids have been implicated in various disease contexts. Unfortunately, the design of specific rhomboid inhibitors has lagged behind, and previously described small molecule inhibitors displayed insufficient potency and/or selectivity. Using a computer-aided approach, we focused on the discovery of novel scaffolds with reduced liabilities and the possibility for broad structural variations. Docking studies with the E. coli rhomboid GlpG indicated that 2-styry…

0301 basic medicineProteasesSerine Proteinase InhibitorsStereochemistrymedicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceBiochemistryStyrenesSerine03 medical and health sciencesCatalytic DomainEndopeptidasesDrug DiscoveryEscherichia coliSerinemedicineAnimalsChymotrypsinDrosophila ProteinsHumansMolecular BiologyEnzyme AssaysSerine proteaseProtease030102 biochemistry & molecular biologybiologyBenzoxazinonesChemistryEscherichia coli ProteinsRhomboid proteaseRhomboidOrganic ChemistryMembrane ProteinsTransforming Growth Factor alphaBenzoxazinesDNA-Binding ProteinsMolecular Docking Simulation030104 developmental biologyDocking (molecular)Mutationbiology.proteinMolecular MedicineCattleDrosophilaBioorganic & Medicinal Chemistry Letters
researchProduct

JAK2 mediates lung fibrosis, pulmonary vascular remodelling and hypertension in idiopathic pulmonary fibrosis: an experimental study

2018

BackgroundPulmonary hypertension (PH) is a common disorder in patients with idiopathic pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators approved for PH have failed in improving IPF mainly due to ventilation (V)/perfusion (Q) mismatching and oxygen desaturation. Janus kinase type 2 (JAK2) is a non-receptor tyrosine kinase activated by a broad spectrum of profibrotic and vasoactive mediators, but its role in PH associated to PH is unknown.ObjectiveThe study of JAK2 as potential target to treat PH in IPF.Methods and resultsJAK2 expression was increased in pulmonary arteries (PAs) from IPF (n=10; 1.93-fold; P=0.0011) and IPF+PH (n=9; 2.65-fold; P<0.00…

0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialtyHypertension PulmonaryBlotting WesternMyocytes Smooth MuscleFluorescent Antibody TechniqueVasodilationVascular RemodelingReal-Time Polymerase Chain ReactionVascular remodelling in the embryo03 medical and health sciencesIdiopathic pulmonary fibrosisTransforming Growth Factor betaRight ventricular hypertrophyInternal medicinepulmonary hypertensionAnimalsHumansMedicineRNA Small InterferingRats WistarCells CulturedCell ProliferationBKCaJanus kinase 2biologybusiness.industryEndothelial CellsJanus Kinase 2idiopathic pulmonary fibrosismedicine.diseaseImmunohistochemistryPulmonary hypertensionIdiopathic Pulmonary FibrosisTriterpenesRatsPhenotype030104 developmental biologyJAK2biology.proteinCardiologyAnimal studiesJanus kinasebusinessSignal TransductionPulmonary artery smooth muscle cells Pulmonary artery endothelial cells.Thorax
researchProduct

A phase 2 study of galunisertib (TGF-Β R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).

2017

4097 Background: TGFβ signaling is associated with HCC progression. Inhibition of TGFβ R1 potentiates activity of sorafenib in in-vitro and in-vivo models. Here we report the clinical activity of galunisertib (G) plus sorafenib (S) in pts with incurable HCC and no prior systemic therapy. Methods: Eligibility criteria included incurable HCC with measurable disease per RECIST 1.1, no prior systemic therapy, Child Pugh A, ECOG PS ≤1.G was administered as 80 mg PO BID (lead-in Cohort 1) or 150 mg PO BID (lead-in Cohort 2 and expansion cohort), as intermittent dosing of 14 days on/off (28 days = 1 cycle). S was administered continuously as a 400 mg PO BID. Primary objective was to characterize …

0301 basic medicineSorafenibCancer ResearchPathologymedicine.medical_specialtybusiness.industryPhases of clinical researchmedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisHepatocellular carcinomaCancer researchMedicineGalunisertibIn patientbusinessTransforming growth factormedicine.drugJournal of Clinical Oncology
researchProduct